Date：Sept. 24, 2020
Source: Biomedical Translational Research Institute
Edited by: Wang Zhengkun

The team of Associate Prof. Wu Yangzhe and Prof. Yin Zhinan of JNU's Biomedical Translational Research Institute published its breakthrough research on tumor therapy in the Nature journal Cellular & Molecular Immunology on Sept. 18. The team developed a new anti-tumor cure strategy with Vγ9Vδ2 γδ T cells, which are healthy, strong and cheap without any gene modification. The research results bring new hope for tumor patients, especially those in an advanced stage.
According to the China Cancer Center, there are over 3.8 million new tumors and 2.29 million deaths from tumors in China each year. The incidence and death rate will not decrease and may even go up in 10 years for reasons including pollution, food insecurity and changes in living habits. Although the situation is critical, research on the tumor therapy has made many significant achievements in recent years.

Traditional tumor treatments include surgery, chemotherapy and radiotherapy. Relatively new strategies are gene therapy, targeted therapy and endocrine therapy. Immunotherapy is the latest and the most promising remedy.

 (The research published in CIM)
 

(The anti-tumor strategy with γδT cells extends the lifespan of liver cancer and lung cancer patients significantly)
Led by Wu and Yin, the research is co-conducted by Chief Physician Xu Kecheng's team at Fu Da Hospital, Prof. Tu Wenwei's team at Hong Kong University's Li Ka Shing Faculty of Medicine and Prof. Dieter Kabelitz's team at Kiel University in Germany.